UK seeks own Breakthrough Therapy program

Share this article:

The UK is looking to create a Breakthrough Therapy regulatory pathway. Bloomberg reports that Under Secretary of State Frederick Curzon told an audience at the Empower Access to Medicines meeting that the government was “at an advanced stage” of establishing an expedited approval process similar to the FDA's.

The US set up the program in 2012, and has received 92 requests. Genentech's Gazyva, J&J/Pharmacyclics Imbruvica and Gilead's Sovaldi are among the breakthrough therapy designated drugs that have been approved.

Bloomberg notes that while the European Medicines Agency still governs what gets approved for the region, Britain's Medicines and Healthcare Products Regulatory Agency has say over how clinical trials are conducted and monitored in the UK.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.